Targeted Therapy in Hema Malignancies (CD20, CD30, CD33, BCR/ABL, FLT3, IDH1/2)
Brian Primeaux, PharmD, BCOP
Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
Jonathan Riess, MD, MS
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (NO)
Cesar A. Santa-Maria, MD, MSCI
Controversy in Breast Cancer- Should be pCR Be an Acceptable Endpoint for Approval of New Therapies for Early-Stage Breast Cancer (YES)
Lajos Puzstai, MD, DPhil, FASCO
Applying New Endocrine and Targeted Agents to the Treatment of Hormone Receptor Positive, HER2 Negative Breast Cancer
Mariana Chavez-McGregor, MD, MSc, FASCO
Antibody Drug Conjugates for HER2 Negative Breast Cancer: A Revolution in Chemotherapy for Breast Cancer
Hope S. Rugo, MD, FASCO
Artificial Intelligence and Modern Medical Practice: Do’s and Don’ts
Eduardo Smith Singares, MD, FACS, FCCM
Lifestyle Modifications in Reducing Risk of Recurrence
Adrienne M. Vazquez Guerra, MSN, ACNP-BC, AOCN®
